12/06/2026 Jazz Pharmaceuticals' Zepzelca Phase 3 LAGOON Trial Misses Primary Endpoint in Second-Line SCLC AbbVie's Venetoclax Shows Sustained 9-Year Efficacy in First-Line CLL at EHA 2026 Jazz Pharmaceuticals' Zepzelca Phase 3 LAGOON Trial Misses Primary Endpoint in Second-Line SCLC (Ref) The Phase 3 LAGOON trial, evaluating Zepzelca (lurbinectedin) in relapsed/second-line metastatic small cell lung cancer (SCLC), did not meet its primary endpoint of overall survival (OS) fo